Clinical Trials | Page 30 | Aplastic Anemia and MDS International Foundation

Clinical Trials

Clinical research is at the heart of all medical advances, identifying new ways to prevent, detect or treat disease. If you have a bone marrow failure disease, you may want to consider taking part in a clinical trial, also called a research study.

We are currently in the process of updating this section. For immediate information, please use the following links to view clinical trials listed on clinicaltrials.gov:

Unrelated Donor Stem Cell Transplantation

Status(es): Recruiting
Study Date(s): Tuesday, March 1, 2005 to Friday, January 1, 2021
Disease(s): aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH)
Age Group: 18 years to 69 years
The purpose of this study is to provide an opportunity for patients with malignancies or bone marrow failure states who lack a suitable sibling donor to undergo allogeneic hematopoietic progenitor cell transplantation using cells from unrelated individuals or cord blood registries.

Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Status(es): Recruiting
Study Date(s): Friday, May 1, 2015 to Wednesday, May 1, 2019
Disease(s): myelodysplastic syndromes (MDS)
Age Group: 18 years to 75 years
This randomized phase II trial studies how well vaccine therapy works in reducing the frequency of cytomegalovirus severe infections (events) in patients with hematologic malignancies undergoing donor stem cell transplant. Vaccines made from a peptide may help the body build an effective immune response and may reduce cytomegalovirus events after donor stem cell transplant.

Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS

Status(es): Recruiting
Study Date(s): Sunday, January 1, 2012 to Sunday, January 1, 2017
Disease(s): myelodysplastic syndromes (MDS)
Age Group: 2 years to 89 years
Phase II trial combining azacitidine with valproic acid as maintenance therapy post allogeneic stem cell transplantation in patients with high-risk MDS/AML. We hypothesize that adding valproic acid to azacitidine will improve outcomes via both direct anti-tumor and immunologically mediated antitumor response with alloreactive donor lymphocytes, having an additive effect and extending 1 year survival in patient with high-risk AML/MDS after hematopoietic stem cell transplant. Based on aforementioned data from the US Department of Health and Human Services, standard 1 year survival for AML...

Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes

Status(es): Recruiting
Study Date(s): Friday, November 1, 2013 to Thursday, December 1, 2016
Disease(s): myelodysplastic syndromes (MDS)
Age Group: 18 years and older
This phase I trial studies the side effects and the best dose of vosaroxin when given together with azacitidine in treating patients with myelodysplastic syndromes. Drugs used in chemotherapy, such as vosaroxin and azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia (VITAL)

Status(es): Recruiting
Study Date(s): Tuesday, March 1, 2016 to Wednesday, January 2, 2019
Disease(s): myelodysplastic syndromes (MDS)
Age Group: 18 years and older
This phase II trial studies how well vosaroxin and cytarabine work in treating patients with untreated acute myeloid leukemia. Drugs used in chemotherapy, such as vosaroxin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy

Status(es): - Unknown -
Study Date(s): Tuesday, October 1, 2013 to Monday, October 1, 2018
Disease(s): myelodysplastic syndromes (MDS)
Age Group: 18 years and older
Study WCMC IST/VOS/MDS evaluates the safety and tolerability of escalating doses of vosaroxin in adult patients with pathologically confirmed Myelodysplastic Syndrome, or MDS, (< 20% blasts in bone marrow, peripheral blood, or both) by World Health Organization (WHO) classification with an intermediate 2 (INT-2) or high-risk score (ie, ≥ 1.5) as assessed by the International Scoring System (IPSS) after failure of hypomethylating agent-based therapy. Based on 3 completed studies and xenograft models, Vosaroxin is hypothesized to be safe and will effective in this patient population.

WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Status(es): Recruiting
Study Date(s): Friday, April 1, 2016 to Thursday, April 1, 2021
Disease(s): myelodysplastic syndromes (MDS)
Age Group: 18 years and older
This randomized phase II trial studies how well WEE1 inhibitor AZD1775 with or without cytarabine works in treating patients with acute myeloid leukemia or myelodysplastic syndrome that has spread to other places in the body and usually cannot be cured or controlled with treatment. WEE1 inhibitor AZD1775 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from...

Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Status(es): Recruiting
Study Date(s): Sunday, January 1, 2012 to Thursday, December 1, 2016
Disease(s): myelodysplastic syndromes (MDS)
Age Group: 18 years and older
This phase I trial studies the side effects and maximum tolerated dose of yttrium Y 90 anti-cluster of differentiation 45 (CD45) monoclonal antibody BC8 (90Y-BC8) followed by donor stem cell transplant in treating patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), ormyelodysplastic syndrome (MDS) that is likely to come back or spread. Giving chemotherapy drugs, such as fludarabine phosphate (FLU), and total-body irradiation (TBI) before a donor peripheral blood stem cell (PBSC) or bone marrow transplant helps stop the growth of cancer or abnormal cells and helps...